NOT that I remotely suggesting it statistically significant at only 15 patients (or being critical of MSB before the usual recriminations start) but MSB's recent GvHD trial reported:
"Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children or adults with SR-aGVHD who received best available therapy (BAT) or the only approved agent in adults".
CYP reported "Patients treated with CYP-001 had a two-year overall survival rate of 60% (9/15 patients)" by comparison in its small phase 1 trial.
Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT, page-2
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
0.005(1.85%) |
Mkt cap ! $49.39M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 27.5¢ | $6.183K | 22.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 32514 | 3 |
View Market Depth
| Last trade - 11.18am 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.5¢ |
Change
0.005 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| 28.0¢ | 28.0¢ | 27.0¢ | 21201 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| CYP (ASX) Chart |